Adenine-induced hyperphosphatemia in a murine model of renal insufficiency

Elizabeth A Bobeck1, Michelle L Piccione2, Jeff W Bishop2, Tyler G Fulmer2, Denise J Schwahn3, Christian Helvig4, Martin Petkovich4,5 and Mark E Cook*2

1Animal Science Department, Iowa State University, Ames, Iowa, USA
2Animal Sciences Department, University of Wisconsin-Madison, Madison, Wisconsin, USA
3Research Animal Resources Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
4Cytochroma Inc., Markham, Ontario, Canada
5Department of Biomedical and Molecular Sciences and Cancer Research Institute, Queen’s University, Kingston, Ontario, Canada

Abstract

Hyperphosphatemia in chronic kidney disease (CKD) patients is a risk factor for cardiovascular events, progressive kidney failure, and mortality. Improved therapeutic interventions to control hyperphosphatemia depend greatly on robust animal models that recapitulate the CKD disease process. Murine-based models of CKD as compared to rat models present significant advantages due to available genetic knockout lines that permit mechanistic dissection of CKD etiologies. The rat adenine model of renal failure has been extensively studied, and studies are now emerging describing adenine-induced renal failure in murine models. However, these newly developed murine models have not fully described the responses to calcitriol and phosphate binders, and the reported effects of adenine on serum phosphate is often lacking in murine models. Therefore, the objectives of this study were: 1) To induce hyperphosphatemia in mice using adenine with minimal mortality, and 2) Report the influence of calcitriol and phosphate binders on the disease process through measurement of serum phosphate and histology. In one approach, C57BL/6 male mice gavaged with 4 or 6 mg adenine/day, as compared to 0 mg adenine/day developed hyperphosphatemia, with low mortality. In a second approach, calcitriol exacerbated adenine-induced increases in serum phosphate at day 7 of adenine administration (p<0.05). Notably, adenine treated mice had 4-fold increased stomach weights vs. non-adenine treated mice (p<0.0001). The addition of a phosphate binder (experiment 3, sevelamer hydrochloride) was ineffective at preventing an adenine-induced increase in blood phosphate, a finding that likely resulted from adenine's inhibition of gastric emptying. We report the successful use of adenine to induce hyperphosphatemia, that the hyperphosphatemic status is exacerbated by calcitriol, and a limitation of the model for studying oral therapies for hyperphosphatemia.

Abbreviations: FGF23: Fibroblast growth factor-23; CKD: Chronic kidney disease

Introduction

Hyperphosphatemia, a sequela of chronic kidney disease (CKD), is responsible for decreased survival due to coronary artery disease, among other complications [1,2]. High blood phosphate levels in CKD patients are controlled by consuming diets low in inorganic phosphate, prescription of oral phosphate binders to bind dietary inorganic phosphate, and in the case of end stage failure, dialysis [3]. Improved methods to treat hyperphosphatemia are needed, as recent work capturing patient compliance reported that up to 45% of patients do not follow prescribed guidelines for use of oral phosphate binders [4,5]. Furthermore, concurrent active vitamin D supplementation prescribed due to a reduced ability of the kidney to convert vitamin precursors to active vitamin D further exacerbates phosphate absorption [6,7]. Previously, the rat models including the 5/6 nephrectomy and adenine-induced kidney insufficiency rat model have been extensively used for pre-clinical testing in the development of therapies for chronic kidney disease [8-10]. The rat adenine-induced kidney insufficiency model is a less invasive refinement over the 5/6 nephrectomy surgical renal insufficiency model [11,12], and was found useful in the development of sevelamer hydrochloride (Sev HCl) as an oral therapy for treatment of hyperphosphatemia [10]. Rats fed 0.75% dietary adenine for two weeks developed increased blood phosphate, FGF23, and blood urea nitrogen due to renal insufficiency, appearing sufficient to model human CKD [8,9,11].

Only recently have murine models of CKD employed the use of adenine; a desirable extension of the rat model due to ease of genetic manipulation and conservation of testable compounds [2,13-16]. Male C57BL/6 mice supplemented with 0.25% adenine had an accumulation of collagen and 2,8-dihydroxyadenine in renal tubules and an accompanying macrophage infiltrate [13]. Adenine-induced histological changes and select blood parameters in male C57BL/6 mice fed 0.75% adenine has also been described [14], and reported that 0.75% adenine was lethal by day 6. Neither report evaluated the effects on blood phosphate status, a hallmark of human CKD. In a separate report, authors found that C57BL/6 mice fed 2% adenine in a casin-based diet had inconsistently increased serum phosphate over a d10-60 exposure period [15]. In a preliminary study in our laboratory, C57BL/6 male mice fed 0.25% or higher adenine showed outright food

Correspondence to: Mark E Cook, Animal Science Department, 1675 Observatory Drive, University of Wisconsin, Madison, WI, 53706, USA, Fax: 6082625157; Tel: 6082627747; E-mail: mcook@wisc.edu

Key words: hyperphosphatemia, renal insufficiency, chronic kidney disease, adenine

Received: May 28, 2017; Accepted: June 16, 2017; Published: June 19, 2017
were read using a SpectraMax190 Plate reader (Molecular Devices, the second was blanked using saline (control for each sample). Plates were loaded onto 2 duplicate plates; one for phosphorus reagent and MI, P7516) and inorganic phosphorus standard (P7516-STD). Samples using the Pointe Scientific inorganic phosphorus reagent set (Canton, Nunc Immunosorp flat-bottomed plate (Fisher Scientific, Rockford, Il) accomplished once daily for 14 days using an 18-gauge curved feeding assigned to each of the following gavage treatments where gavage was during a 7-day acclimatization period. This diet contained 6.85 g formulated based on the AIN-76A diet (TD.94060, Harlan-Teklad) during the study of oral therapies for preventing hyperphosphatemia.

Therefore, the objectives of this study were to: 1) Find a gavage dose of adenine that induced hyperphosphatemia without causing mortality; 2) Test the influence of calcitriol (a common active vitamin D therapy for CKD patients, and also known to increase phosphate absorption) in the mouse adenine model; and 3) Determine if sevelamer HCl, a phosphate binder, prevents hyperphosphatemia in the mouse adenine model. Here, we report successful induction of hyperphosphatemia that was exacerbated by calcitriol supplementation. We also found that adenine interferes with gastric emptying; a limitation of this model in the study of oral therapies for preventing hyperphosphatemia.

Materials and methods

Experiment 1
All animal experimental procedures were approved by the University of Wisconsin-Madison College of Agricultural and Life Sciences Animal Care and Use Committee. Animals were housed in a facility with accreditation from AAALAC for the duration of the experiment. Adult male C57BL/6 7-8 weeks of age with littermate identity (Harlan Teklad, Madison, WI, n=36, 12 per treatment) were housed 3 per shoebox cage, as littersmates, with a 12 h light/dark cycle. Mice were allowed free access to distilled water and a semi-purified sucrose/casein based diet (TD.10050, Harlan-Teklad, Madison, WI) formulated based on the AIN-76A diet (TD.94060, Harlan-Teklad) during a 7-day acclimatization period. This diet contained 6.85 g calcium/kg diet and 5.61 g phosphate/kg diet, with a calcium:phosphate ratio of 1.22. Following acclimatization, 12 mice (4 cages of 3 mice) were assigned to each of the following gavage treatments where gavage was accomplished once daily for 14 days using an 18-gauge curved feeding needle: 1.200 µl ddH₂O oral gavage; 2.4 mg adenine (99.8% pure, Calbiochem, La Jolla, CA) in 200 µl ddH₂O; or 3.6 mg adenine in 200 µl ddH₂O. As mice were expected to lose weight and body condition due to adenine treatment during induction of renal insufficiency, mice were removed from the experiment if they were observed to not eat or drink, or when body weight loss was >40%. Mice were weighed weekly and then bled under light isoflurane anesthesia using the axillary bleeding method at day 7 or 14 of the experimental gavaging period (6 mice were euthanized per time point). Euthanasia after bleeding under anesthesia was performed by cervical dislocation. Blood was collected into 400µl serum separator tubes (BD Medical, Franklin Lakes, NJ) and serum was separated and stored at -80°C until phosphate, urea, and FGF23 were analyzed. The right kidney of each mouse was weighed separately for determination of kidney weight as a percentage of bodyweight.

Serum analysis
To determine serum phosphate, samples were analyzed in a 96-well Nunc Immunosorp flat-bottomed plate (Fisher Scientific, Rockford, IL) using the Pointe Scientific inorganic phosphorus reagent set (Canton, MI, P7516) and inorganic phosphorus standard (P7516-STD). Samples were loaded onto 2 duplicate plates; one for phosphorus reagent and the second was blanked using saline (control for each sample). Plates were read using a SpectraMax190 Plate reader (Molecular Devices, Sunnyvale, CA) with the SoftMax Pro 4.7.1 analysis program (Molecular Devices, Sunnyvale, CA). Blanked values (phosphorus reagent-blank) were used to calculate final OD’s to reduce overestimation of serum phosphate in the event of red blood cell lysis. Hence, the presence of lysis was indicated in results in Experiment 1.

Urea was analyzed in a 96-well plate using mouse serum and BioAssay Systems Quantichrom Urea Assay Kit according to manufacturer’s instructions (DIUR-500, Hayward, CA). Remaining samples were analyzed using the Mouse FGF23 C-terminal ELISA kit (Immutopics International, San Clemente, CA) according to manufacturer directions. Control samples (no adenine) were not diluted for the FGF23 analysis; however, serum from adenine-treated animals was diluted 1:10 using C-term sample diluent (Immutopics International, San Clemente, CA) in order to assure samples were within the standard curve.

Experiment 2
Adult male C57BL/6 7-8 weeks of age with littermate identity (Harlan Teklad, n=72, 18 per treatment) were housed 3 per cage with a 12 h light/dark cycle and fed a semi-purified sucrose/casein-based diet based on AIN76-A (Harlan Teklad TD.110109). Following a 7-day acclimatization period, mice were assigned to one of 4 daily gavage treatments in order to determine the interaction of calcitriol (active Vitamin D) and renal failure, and resulting phosphate status: 1) 200 µg calcitriol; 2) 200 µg corn oil supplying 0.5 µg/kg body weight/day calcitriol (Enzo Life Sciences, Farmingdale, NY); 3) 200 µg corn oil containing a suspension of 4 mg adenine; 4) 200 µg corn oil supplying 0.5 µg/kg bodyweight/day calcitriol plus 4 µg adenine. Corn oil was used as a vehicle to accommodate calcitriol. Adenine dose (4 mg/ day) was selected based on results from experiment 1, which was the lowest dose of adenine that led to kidney dysfunction as measured by increased kidney weight, plasma urea, FGF23, and serum phosphate. Animals were gavaged for 14 days, weighed weekly, monitored, and bled as described in experiment 1. Additionally, stomachs were collected, weighed, and expressed as percentage of bodyweight.

Experiment 3
Adult male C57BL/6 7-8 weeks of age with littermate identity (Harlan Teklad, n=48, 12 per treatment) were housed 3 per cage with a 12 h light/dark cycle. Mice were fed the diet as described in experiment 1 with or without a phosphate binder (1% sevelamer HCl, Genzyme Corporation, Cambridge, MA; replacing a cellulose filler in the diet) and with or without daily adenine gavage (0 or 4 mg/day in 200 µl ddH₂O, as described above) to provide the following treatment groups; 1) Control diet with 0 mg adenine gavage; 2) 1% dietary sevelamer HCl with 0 mg adenine gavage; 3) Control diet with 4 mg adenine gavage; or 4) 1% dietary sevelamer HCl with 4 mg adenine gavage. Concentration of sevelamer was based on previous experiments in chick diets where 1% was successful in reducing plasma phosphate and bone ash [17], as well as the calculation that 1 g sevelamer can bind 0.45 g phosphate, hence 1% sevelamer could bind up to 80% of the phosphate in the mouse diet (which contains 0.56% phosphate [18]). The remaining 0.13% phosphate in the diet would leave the mice severely deficient. Diets were fed for 2 weeks and mice were bled, organs were collected, and serum was analyzed as described above.

Kidney histology
Upon sacrifice, kidneys were weighed and then transferred into 10% buffered formalin (Fisher Scientific, Waltham, MA) for 24-hour fixation at room temperature. Individual kidneys were embedded in

---

**Nephrol Renal Dis, 2017 doi: 10.15761/NRD.1000126**

---
paraffin, sectioned, and stained with hematoxylin and eosin (H&E) before analysis by a board licensed veterinary pathologist (Author: DJS). Kidneys selected for photos were representative samples of 7- and 14-day controls, 7- and 14-day with 4 mg adenine gavage, 7- and 14-day with 6 mg adenine gavage, and 7-and 14-day 4 mg gavage with calcitriol supplementation. Photos were taken at 200x on a Nikon Eclipse 50i Microscope (Melville, NY).

**Statistical analyses**

Data were analyzed using a one-way ANOVA for experiment 1, and a two-way ANOVA with a 2×2 factorial arrangement of treatments in experiments 2 and 3 (experiment 2: with or without adenine and/ or active D (calcitriol), experiment 3: with or without adenine and/or sevelamer HCI) (SAS Institute Inc., Cary, NC). Data in experiment 2 were analyzed for main effects of adenine, VitD (calcitriol), and the adenine X VitD interaction. Data in experiment 3 were analyzed for adenine, sevelamer HCl, and the adenine X sevelamer HCl interaction. Post-ANOVA analyses comparisons of mean treatment differences were conducted even if the interactions were not significant (p<0.05) using least squared differences such that significant effects could be easily discerned. The p values for main effects and interactions were provided for discernment regarding the least square differences. Data were expressed as mean and the overall standard error of the mean for each variable was provided.

**Results**

**Experiment 1**

The goal of this experiment was to identify a minimum level of gavaged adenine that induced hyperphosphatemia but did not increase mortality. In a preliminary trial (not shown), mice were gavaged with 0, 1, or 3 mg adenine per day. After two weeks, average serum phosphate of the three groups were 7.0, 6.9, and 7.6 mg/dL, respectively, hence higher doses of adenine (>3 mg/day) appeared necessary to effectively induce hyperphosphatemia. In experiment 1, gavaging 6 mg adenine per day for 7 days significantly increased serum phosphate by 2.1-fold compared to 0 mg control (p<0.01); at 14 days, gavaging 4 or 6 mg adenine per day significantly increased plasma phosphate above a vehicle gavaged control (p<0.01, Table 1). Gavaging adenine decreased weight at both 7 and 14 days versus vehicle control (p<0.001), but mortality remained minimal with only 1 mouse in the 4 mg and 2 mice in the 6 mg groups requiring euthanasia before reaching their scheduled endpoint (day 7 or 14).

At day 7 and 14 days of treatment, 4 and 6 mg adenine/day increased serum FGF-23 (1.193-fold, p<0.0001), urea (4-fold, p<0.0001), and relative kidney weights (1.5-fold, p<0.0001). Adenine gavaged mice had reduced body weight (13% to 25%, p<0.001) when compared to mice not receiving adenine. Increase in adenine gavage from 4 to 6 mg/day did not impact variables measured except for FGF-23 at day 7, where 6 mg treated mice had an additional increase in serum FGF-23 compared to 4 mg treated mice.

**Experiment 2**

Supplemental calcitriol (active vitamin D) is known to increase phosphate absorption [6,7,19]. The goal of experiment 2 was to determine the interaction of active vitamin D and adenine on phosphate metabolism during renal dysfunction (Table 2). For all variables measured, the addition of adenine (main effect: adenine) significantly increased serum phosphate, FGF23, urea, stomach and kidney weights, while decreasing body weight. While calcitriol had no impact on variables measured in the absence of adenine treatment (independent of interactions), calcitriol in the presence of adenine-induced renal failure altered biomarkers of abnormal phosphate homeostasis (Adenine X D Interaction). Calcitriol, when combined with adenine, increased serum phosphate (day 7 only, 1.2-fold, p<0.05), FGF23 (>2-fold, p<0.0001), relative kidney weight (1.1-fold, p<0.05) and reduced body weight (≥8%, p<0.01) compared to the adenine supplementation without calcitriol. During necropsy for determining kidney weights (Figure 1), it was observed that stomachs were enlarged; hence stomachs were collected and weighed (Figure 2). Apart from the enlargement (approximately 4-fold) due to adenine treatment (p<0.0001), calcitriol had no effect on stomach tissue weights (emptied and weighed). Total mortality, including euthanasis according to protocol and before endpoints, was 0 in control mice, 1 in + vitamin D mice, 3 in + adenine mice, and 4 in + adenine + vitamin D mice.

**Experiment 3**

In experiment 3, the effectiveness of the phosphate binder, sevelamer HCl to prevent adenine-induced hyperphosphatemia was investigated (Table 3). Sevelamer HCl was ineffective at preventing an adenine-induced increase in blood phosphate, urea, relative stomach weight and decreased body weight. On day 14, but not day 7, sevelamer reduced adenine induced increases in serum FGF23 (adenine X sevelamer, p=0.0017). Increases in kidney weight induced by adenine by day 14, but not day 7, was exacerbated by sevelamer treatment (adenine X sevelamer, p=0.04). As observed in experiment 2, adenine administration increased full and empty stomach weights by 3 and 1.4-fold, respectively (p=0.0007) when compared to mice that received no supplemental adenine or sevelamer HCl. The addition of sevelamer HCl to the adenine treatment increased full and empty stomach

---

**Figure 1.** Excised kidneys of mice from experiment 2 at day 14 either gavaged with 4mg adenine/ day (A) or 0mg (vehicle) (B). Mice were orally gavaged 0 or 4mg adenine for 2 weeks and kidneys were excised for appearance and weight determination. The main effect of adenine on increasing kidney weight was significant at p<0.0001. Note the lighter color of adenine treated mice (A).

**Figure 2.** Excised full stomachs of mice from experiment 2 at 14 days either on control+0mg (vehicle) (2A) or control+4mg adenine/ day (2B). Mice were orally gavaged 0 or 4mg adenine for 2 weeks and kidneys were excised for appearance and weight determination. The main effect of adenine on increasing stomach weight was significant at p<0.0001.
weights, when compared to mice only receiving adenine treatment. All mice in non-adenine treated groups survived until scheduled endpoint. One mouse was euthanized in the adenine treatment group, and two in the adenine+sevelamer HCl treatment group.

**Histology**

Figures 3A and 3B show kidney sections of control mice at 7 and 14 days with normal renal cortices. At 7 and 14 days for mice receiving the 4 mg or 6 mg adenine gavage, kidney tubules show distention with dilated, degenerating epithelium and material that may represent crystallizing adenine metabolites consistent with previous adenine-induced kidney injury models [20] (Figures 3C-3F). An increase in interstitial fibroblasts is seen in 6 mg gavage at 14 days (Figure 3F). Kidneys of mice gavaged for 7 or 14 days with 4 mg adenine + calcitriol supplementation had similar kidney injuries as mice gavaged with 4 mg adenine for 7 or 14 days without additional calcitriol supplementation (Figures 3G-3H). The effect of vitamin D toxicoses (corticomedullary junction mineralization) from 14 day calcitriol supplementation is seen in Figure 3H. In all cases of adenine gavage, crystallization is more evident at 14 days than at 7 days.

**Discussion**

Rats have been the model of choice for studying adenine-induced hyperphosphatemia, and the advantages of murine-based adenine models have been recently realized and reported by several investigators [2,15,16,21]. A reliable model of chemically-induced hyperphosphatemia in mice is useful since mice require less test compound and knockouts are widely available for studying basic mechanisms involving hyperphosphatemia. It has been demonstrated that mice have a relatively higher sensitivity to adenine-induced toxicity than rats. Rats tolerate dietary levels of adenine at 0.75% for prolonged periods (8 weeks or more) [9,11,19,22], whereas mice show
Figure 3. Histology of sliced H&E stained kidneys from selected groups in murine adenine-induced kidney insufficiency studies. In panels A-F, C57Bl/6 mice were treated with either 0, 4, or 6 mg adenine/day (rows) in 200ul ddH2O for 7 or 14 days (columns). In panels G and H, mice were gavaged with 4mg adenine/day + active vitamin D in corn oil (7 or 14 days), and the 0mg/day adenine corn oil control were reflective of panels A and B. Kidneys were fixed in formalin for 24 hours at room temperature and then transferred to PBS until sectioning and staining with H&E.

A: 7 day control, non-adenine treated control mouse. Normal renal cortex. GL, glomerulus. 200X;
B: 14 day control, non-adenine treated control mouse. Normal renal cortex. 200X;
C: 7 day 4 mg. Renal tubules are frequently distended. Some contain amorphous clear or pale brown crystals (*) and are lined by attenuated, degenerating epithelium (E). Brightly eosinophilic intratubular material that may represent crystallizing adenine metabolites is present at low levels (arrowhead). 200X;
D: 14 day 4 mg. Renal tubules often contain spiky brown crystals, presumed to be adenine metabolites, as they resemble the crystals seen in the Aprt knockout mouse [20]. The crystals occasionally induce epithelial necrosis and subsequent suppurative inflammation (S). Tubular epithelium is often attenuated and flattened (regeneration). Crystals in various stages of nucleation are noted (*). 200X;
E: 7 day 6 mg. Renal tubules are markedly degenerate and dilated; they are commonly lined by attenuated, degenerating epithelium (E) and contain necrotic cellular debris (N) (degeneration). Eosinophilic material interpreted as crystallizing adenine metabolites is noted (arrowhead). 200X;
F: 14 day 6 mg. Large numbers of spiky brown crystals (adenine metabolites) are noted within renal tubules. They appear to induce epithelial proliferation (P), thereby “coating” themselves in degenerate epithelium. Many tubules are lined by flattened, attenuated (regenerating) epithelium, and there is an increase in interstitial cells (fibroblasts). 200X;
G: 7 day 4 mg with Vitamin D. Renal tubules are commonly filled with brightly eosinophilic debris (arrowheads); this material is interpreted as crystallizing adenine metabolites. Tubular epithelium is occasionally flattened or irregular (degeneration). 200X;
H: 14 day 4 mg with Vitamin D. Large quantities of brightly eosinophilic intratubular material (arrowheads) interpreted as crystallizing adenine metabolites are noted; there is accompanying tubular degeneration. Tubules at the corticomedullary junction are undergoing mineralization (M), as is consistent with Vitamin D toxicosis. There are increased interstitial fibroblasts and subsequent fibrosis. 200X.
100% mortality by day 6 when fed 0.75% dietary adenine [14]. Renal dysfunction has been shown in mice when fed 0.25% of the diet for up to 28 days; however, when we attempted to study 0.25% adenine in the diet, we saw profound feed refusal (control=3 g/mouse/day, 0.25% adenine≤1 g/mouse/day; unpublished), which presents a problem for studying dietary intervention for the control of hyperphosphatemia. Studies that have investigated adenine-induced renal dysfunction have reported phosphate status in mice; however, serum phosphate was not significantly different from control phosphate at all time points selected post-induction of dietary adenine, likely due to alternating dietary adenine inclusion between 0.15 and 0.20% over a 60 day period [15]. Hence we sought to develop an adenine model that minimized weight loss possibly due to feed refusal, resulted in low or no mortality, effectively induced permanent changes in phosphate status, and did not confound feed intake with several dietary additives (i.e., adenine plus test compounds to alleviate renal dysfunction).

In preliminary gavage experiments, 8 or 9 mg adenine/day was lethal, while adenine at 1 or 3 mg/day failed to induce increases in blood phosphate within a 14-day period (unpublished). In the first dosing experiment shown in this paper, we found that altered phosphate status (e.g. increased serum phosphate and FGF23) could be induced in mice with a 4 mg adenine/day gavage without substantial effects on bodyweight loss, and mortality. The increase in serum phosphate in mice receiving an adenine gavage was similar to what has been reported in studies using rats [8]. Increases in kidney weight and serum urea were consistent with renal dysfunction [11,14]. The marked increase in blood FGF23 has been previously reported during renal failure [8,15,23]. FGF23 is a bone-derived hormone responsible for the regulation of blood phosphate homeostasis and is responsible for increasing renal excretion of blood phosphate by down regulation of the renal sodium–dependent phosphate co-transporter 2a (NaPi2a), a transporter responsible for the renal resorption of phosphate. FGF23 also increases degradation of 1, 25-dihydroxycholecalciferol (active vitamin D) and thereby decreases phosphate absorption from the intestines. Hence, elevated levels of serum FGF23 is indicative of a mechanism to normalize blood phosphate homeostasis in animals with normal renal function.

In the second experiment, we attempted to show that the use of calcitriol (1.25-(OH), D3) would exacerbate the hyperphosphatemic status of renal compromised mice. It is well known that calcitriol increases the transport of dietary phosphate in the intestine by increasing the number of sodium–dependent phosphate co-transporters on the brush border membrane [24]. Patients with CKD are often treated with active vitamin D analogs to maintain calcium homeostasis and control secondary hyperparathyroidism [25]; however, treatment of CKD patients with calcitriol has been shown to increase blood phosphate [6]. In the short experimental period shown in this paper, daily doses of calcitriol increased serum phosphate at day 7 but not day 14. Histology revealed that the mice were undergoing a state of vitamin D toxicity (Figure 3H). Elevated FGF23 in mice treated with calcitriol was likely successful in controlling blood phosphate levels at day 14 by increased renal excretion of phosphate and increased degradation of calcitriol, and thus decreased absorption of dietary phosphate [22]. The reduction in body weight and increased in relative kidney size as a result of supplementing adenine-treated mice with calcitriol further supports that phosphate metabolism was altered by treating mice with calcitriol during renal dysfunction. These findings suggest that the mouse adenine model, as described, could be useful in studying the adverse effects of calcitriol therapy on phosphate homeostasis.

The primary approach to manage hyperphosphatemia in the CKD patient is through oral administration of phosphate binders and dietary phosphate reduction [3,6]. Failure to control the hyperphosphatemic condition in CKD patients significantly increases the risk of cardiovascular disease [27]. Modifying the diet to reduce bioavailable phosphate has limited usefulness, but is likely even less effective when combined with calcitriol therapy. Calcitriol therapy may increase the bioavailability of phytate phosphate by indirect actions of vitamin D [28,29] and direct actions of intestinal alkaline phosphatase [30-32]. Hence, the most useful available therapies for the control of blood phosphate are oral supplements such as phosphate binders.

For an animal model of kidney disease to be useful in the study of oral therapies for the control of hyperphosphatemia, gut function should remain intact. During the gavage studies, it was noted that the stomachs were enlarged in mice treated with adenine. While it had been previously reported that CKD could alter gastrointestinal motility [33], there was no mention in the animal literature of enlarged stomachs [8,13,14]. The significant enlargement of the stomach caused by adenine supplementation suggested that adenine use in the mouse model might compromise oral administration of test therapies. Stomach enlargement was not the result of gavage techniques since control mice did not experience enlarged stomachs (Figure 2; Tables 2 and 3).

To determine if the enlarged stomachs associated with adenine treatment would impair the study of oral supplements to prevent hyperphosphatemia, we studied the interaction of adenine and sevelamer. Sevelamer HCl has been shown to be effective at treating adenine-induced hyperphosphatemia in rats [8,10], and 5/6 nephrectomy-induced hyperphosphatemia in mice [34] and rats [35]. We have recently demonstrated in chicks that sevelamer HCl is effective in preventing the absorption of phosphate liberated from the diet due to the treatment of calcitriol [17]. In this report, we found that while sevelamer HCl caused a modest reduction in serum FGF23 after 14 days of supplementation in adenine treated mice, sevelamer HCl was ineffective at preventing hyperphosphatemia in this model. Sevelamer was supplemented at 1% of the diet, and could potentially bind 0.45% of the 0.56% dietary phosphate. While sevelamer was not fed in excess, the remaining 0.13% phosphate in the diet would have left mice severely deficient had sevelamer bound maximal capacity of phosphate.

It is also likely that sevelamer’s ineffectiveness in this model was due to the effect of adenine on gut emptying [36]. The nearly 4-fold increase in stomach weight due to adenine treatment appeared to be mostly accumulated food. When stomachs were emptied of their contents (contents were diet in appearance), the increase in size due to adenine use was largely lost. These results suggest that effectiveness of sevelamer HCl may have been limited by compromised movement through the stomach to reach and bind phosphate in the small intestine where phosphate is absorbed. To effectively complex phosphate, sevelamer must be in an environment where pH is greater than 5 (such as found in the small intestine); sevelamer is unable to bind phosphate in the stomach where the pH<4 [37]. Future work should be conducted with an increased inclusion of sevelamer (3%) in order to determine the contribution of sevelamer dose versus emptying effect on reducing hyperphosphatemia.

Conclusion

In conclusion, we have successfully refined a murine adenine model of renal dysfunction that can be useful for the study of hyperphosphatemia. The model is responsive to calcitriol as would be predicted, and histology shows that adenine metabolites are
accumulating in kidney tissue and causing mechanical damage, inflammation, and reduced filtration. A limitation of the model would be the study of dietary modifications or oral supplements that are added to the food supply since the use of adenine in the mouse models appears to influence stomach emptying.

**Funding**

Research was supported through royalties received from the Wisconsin Alumni Research Foundation (WARF) and through a sponsored research agreement with Cytochroma, Inc.

**Acknowledgement**

The authors would like to thank Jordan Sand for aiding in sample collection, the UW Animal Care Staff (Terry Jobbis, Dawn Irish, and Angel Gutierrez-Velin) for animal care, and Joan Parrish for photo preparation.

**Declaration of interest**

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

**References**

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lorrie EG, et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol* 15: 2208-2218. [Crossref]

2. Kaladjur vivid JC, Komaba H, Sato T, Erben RG, Baron R, et al. (2017) Klotho expression appears to influence stomach emptying. *Am J Physiol Renal Physiol* 311: F877-F889. [Crossref]

3. Urbari J (2007) Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. *Seminars in Dial 20*: 295-301. [Crossref]

4. Gonzalez-Patru E, Tunon I, Egido J, Ortiz A (2012) Phosphate: a stealthier killer than previously thought? *Cardiovasc Path* 21:5: 372-381. [Crossref]

5. Fisell RB, Karaboyas A, Bieger BA, Sen A, Li Y, et al. (2015) Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS. *Mineral Bone Dis* 20: 38-49. [Crossref]

6. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, et al. (2009) Vitamin D compounds for people with chronic kidney disease requiring dialysis. *Cochrane Database Syst Rev*. [Crossref]

7. Quarles LD (2012) Role of FGF23 in vitamin D and phosphate metabolism: implications for hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uremia. *Nephrol dial transplant* 21: 651-659. [Crossref]

8. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, et al. (2003) Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. *Kidney Int* 64: 441-450. [Crossref]

9. Okada H, Kaneko Y, Yawata T, Uyama H, Osono S, et al. (1999) Reversibility of adenine-induced renal failure in rats. *Japanese Soc Nephrol* 3: 82-88. [Crossref]

10. Fleck C, Appenroth D, Jonas P, Koch M, Kundt G, et al. (2006) Suitability of 5/6 nephrectomy (5/6NX) for the induction of renal interstitial fibrosis in rats—solution of sex, strain, and surgical procedure. *Exp Toxicol Pathol* 57: 195-205. [Crossref]

11. Tamura M, Aizawa R, Mori H, Ozaki H (2009) Progressive renal dysfunction and macrophage infiltration in interstitial fibrosis in an adenine-induced tubulointerstitial nephritis mouse model. *Histochim Cell Biol* 131: 483-490. [Crossref]

12. Morishita Y, Ohtsuki A, Watanabe M, Ishibashi K, Kusano E (2011) Establishment of acute kidney injury mouse model by 0.75% adenine ingestion. *Renal failure* 33: 1013-1018. [Crossref]

13. Ito T, Olaason H, Lindberg K, Amin R, Edvardsen K, et al. (2013) A novel model of adenine-induced tubulointerstitial nephropathy in mice. *BMC Nephrol* 14: 116. [Crossref]

14. Akchurin O, Sureshbabu A, Doty SB, Zhu YS, Patino E, et al. (2016) Lack of hepatic ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease. *Am J Physiol Renal Physiol* 311: F877-F889. [Crossref]

15. Bobeck EA, Meyer KM, Helvig C, Pelikovich M, Cook ME. (2012) Sevelamer Hydrochloride Binds Phosphate Released from Phytate in Chicks Fed Alphahydroxy Cholecalciferol. *J Ren Nutr* 23(1): 21-27. [Crossref]

16. Brezina B, Quini WY, Nolan CR (2004) Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. *Kidney Int Supplement* : S39-S45.

17. Posner GH, Helvig C, Cuervier D, Collop D, Khergerov A, et al. (2010) Vitamin D analogues targeting CYP24 in chronic kidney disease. *J Steroid Biochem Mol Biol* 121: 13-19. [Crossref]

18. Evan AP, Hedhoe SB, Connors BA, Deng L, Liang L, et al. (2001) Sequential analysis of kidney stone formation in the Apet knockout mouse. *Kidney Int* 60: 910-923. [Crossref]

19. Hayashi S, Oe Y, Fushima T, Sato E, Sato H, et al. (2017) Protease-activated receptor 2 exacerbates adenine- induced renal tubulointerstitial injury in mice. *Biochem Biophys Res Commun* 483: 547-552.

20. Helvig CF, Cuervier D, Hosfield CM, Ireland B, Khergerov AZ, et al. (2010) Dysregulation of vitamin D metabolism in the uremic rat. *Kidney Int* 78: 463-472. [Crossref]

21. Seiler S, Heine GH, Fiser D (2009) Clinical relevance of FGF-23 in chronic kidney disease. *Kidney Int Suppl*: S34-S42.

22. Hattenhauer O, Truebert M, Murer H, Biber J (1999) Regulation of small intestinal Na-P(i) type Ib cotransporter by dietary phosphate intake. *Am J Physiol* 275: 7567-762. [Crossref]

23. National Kidney Foundation (2003) KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* 42: S1-S201. [Crossref]

24. Cupisti A, D’Alessandro C, Valeri A, Capitanini A, Meola M, et al. (2010) Food intake and nutritional status in stable hemodialysis patients. *Renal failure* 32: 47-54. [Crossref]

25. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, et al. (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. *J Am Soc Nephrol* 16: 520-528. [Crossref]

26. Biehl RR, Baker DH (1997) Utilization of phytate and nonphytate phosphates in chicks as affected by source and amount of vitamin D3. *J Anim Sci* 75: 2986-2993. [Crossref]

27. Snow JL, Baker DH, Parsons CM (2004) Phytase, citric acid, and 1 alpha-hydroxycholecalciferol improve phosphate utilization in chicks fed a corn-soybean meal diet. *Poultry Sci* 83: 1187-1192. [Crossref]

28. Birge SJ, Avioli LC (1981) Intestinal phosphate transport and alkaline phosphatase activity in the chick. *Am J Physiol* 240: E384-E390. [Crossref]

29. Moriiuchi S, Deluca HF (1976) The effect of vitamin D3 metabolites on membrane proteins of chick duodenal brush borders. *Arch Biochem Biophys* 174: 367-372. [Crossref]

30. Norman AW, Mircheff AK, Adams TH, Spielvogel A (1970) Studies on the mechanism of action of calciferol. 3. Vitamin D-mediated increase of intestinal brush order alkaline phosphatase activity in the chick. *Am J Physiol* 219: 880-884. [Crossref]

31. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, et al. (2003) Sevelamer hydrochloride: mechanisms and clinical implications. *Biochem Biophys Acta* 21: 348-359. [Crossref]

32. Hirako M, Kamiya T, Misu N, Kobayashi Y, Adachi H, et al. (2005) Impaired gastric motility and its relationship to gastrointestinal symptoms in patients with chronic renal failure. *J Gastroenterol* 40: 1116-1122. [Crossref]

33. Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, et al. (2012) Lanthanum carbonate, like sevelamer-HCL, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. *Nephrol dial transplant* 27: 505-513. [Crossref]

34. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, et al. (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. *Kidney Int* 64: 1653-1661. [Crossref]

35. Rehm WS, White AS, Sanders SS, Feagin FF (1970) Adenine compounds on changes in optical density and motility of frog gastric mucosa. *Am J Physiol* 218: 1010-1014. [Crossref]

36. Sprague SM (2007) A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. *Curr Med Res Opin* 23: 3167-3175. [Crossref]

**Copyright:** © 2017 Bobeck EA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.